European Investments: Booming Biotech

Biotech is becoming an increasingly popular investment choice. The coronavirus pandemic has actually created more potential in this field. Mozes Victor Konig – a businessman who has made substantial investments in the industry – has seen a significant uptake in the field himself.   He explained:

“What you have to realize is that this industry really needs the capital because invariably such biotechnological firms require a lot of money to even be able to consider approaching the FDA for approval.”

Konig – who had some trouble with Interpol some years ago which he has now put behind him – particularly likes this industry as he describes it as “exciting, innovative and really helpful to potentially thousands of people.”

In Italy we are now witnessing a boom with biotech too.  One example of this is the recent announcement from Sofinnova Partners (life sciences Paris-based VC firm) of its upcoming investments in three startups via its Sofinnova Telethon Fund (Italy’s largest fund solely dedicated to biotechnology). These companies are: AAVantgarde Bio, Alia Therapeutics and Borea Therapeutics all of which are in the process of creating therapies that could really help with rare genetic diseases.

These three seed investments total €6M and are in line with Sofinnova Telethon Fund’s strategy of working with cutting edge Italian scientists and successful entrepreneurs in an effort to create high-end companies in the genetic disease section of biotechnology.

Potential investors, says Konig: don’t bypass the biotech industry; it’s a great way forward for many reasons.

About James Cannon

James Cannon is an experienced hedge fund analyst. He has served on the advisory boards for various different Fortune 500 companies as well as serving as an adjunct professor of finance. James Cannon has written for a variety of Financial Magazines both on and off line. Contact James at james[at]